Tap video for sound
  • weillcornellMovie: A 3D cell culture organoid derived from tumor cells. Combining genetic info, 3D cell culture & rapid drug screening can identify the best treatment options for patients for whom multiple therapies have failed, shows a new study from Weill Cornell researchers in the journal Cancer Discovery.
    To better treat these patients, Dr. Rubin and the research team — including co-first authors Dr. Chantal Pauli, a former research fellow in Dr. Rubin’s lab, and Dr. Benjamin Hopkins, a postdoctoral associate in co-author Dr. Lewis C. Cantley’s lab — developed an approach in which tumor cells taken from patients are grown into three-dimensional cell cultures called tumor-derived organoids. The researchers can then test more than 120 U.S. Food and Drug Administration-approved cancer drugs against the organoids to determine which drugs show the most promise. After identifying a potential treatment, they transplant the organoid into a mouse to assess how well the tumor responds to the drug. The organoid cell culture system, Dr. Rubin said, markedly accelerates the identification of potential therapies compared with current approaches.
    This study was supported in part by the National Institutes of Health, the Starr Cancer Consortium and the Prostate Cancer Foundation @pcfnews.
    #cancer #cancerresearch #precisionmedicine #CareDiscoverTeach #WeillCornellMedicine

Log in to like or comment.